Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Summary

Undifferentiated thyroid cancer is the most malignant tumor of the thyroid gland, with a median survival of only 3 months. Most undifferentiated cancers lose the chance of surgery when they are first diagnosed. The current study, Nexavar, is used only for dedifferentiated thyroid cancer and has not been applied to undifferentiated cancer. This study attempted to apply it to preoperative treatment of undifferentiated cancer to see if it would shrink the tumor and give the patient an opportunity for surgery.

Timeline

Start

2018-05-01

Primary completion

2020-12-30

Completion

2020-12-30

Drugs

Indications